<DOC>
	<DOCNO>NCT00828750</DOCNO>
	<brief_summary>An open-label , dose-adjustment extension study evaluate safety efficacy eltrombopag treatment subject ITP previously enrol eltrombopag trial TRA108109 ( NCT00540423 ) .</brief_summary>
	<brief_title>Clinical Evaluation Eltrombopag Chronic Idiopathic Thrombocytopenic Purpura ( ITP )</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Subject sign dated write informed consent . Subject ( &gt; =20 year ) diagnose ITP . Subject previously enrol TRA108109 ( NCT00540423 ) must complete treatment followup period define protocol . Subject intercurrent medical event risk thrombosis thrombophilia . Prolongation prothrombin time activate partial thromboplastin time ( aPTT ) must within 1.2 time upper limit normal range history hypercoagulable state . A complete blood count ( CBC ) , within reference range , follow exception : Hemoglobin : patient haemoglobin level &lt; low limit normal eligible inclusion hemorrhage present . Neutrophil count &gt; = 1,500/L ( 1.5x10E9/L ) require inclusion . The following clinical chemistry MUST NOT exceed 1.2 time upper limit normal reference range : creatinine , total bilirubin alkaline phosphatase . The following clinical chemistry MUST NOT exceed 2 time upper limit normal reference range : ALT AST . Albumin must less 80 % low limit normal . Female subject must either : nonchildbearing potential ( hysterectomy , bilateral oophorectomy , bilateral tubal ligation postmenopausal &gt; 1 year ) , childbearing potential negative pregnancy test agree use contraceptive method specify GSK List Highly Effective Methods Avoidance Pregnancy two week prior administration study medication , throughout study , 28 day completion premature discontinuation study : Reticulocyte count within reference range elevate case bleeding . Any severe medical condition ( cardiac , hepatic renal disorder ) chronic ITP . ( Note : `` Severe '' define &gt; = Grade 3 rule accord `` Classification Severity Adverse Experiences ( PAB/SD Notification No.80 , date 29 June 1992 ) History suspect confirm arterial venous thrombosis ( e.g. , myocardial infarction , deep vein thrombosis ) within last 1 year . History drug/alcohol abuse dependence within last 1 year . Suspected blood disorder ITP . Suspected platelet aggregation abnormality . Suspected cyclic thrombocytopenia . Suspected Evans Syndrome . Subjects meet GSK Liver Stopping Criteria previous eltrombopag study TRA108109 ( NCT00540423 ) . Current history HIV infection hepatitis B virus hepatitis C virus infection . Current malignancy history malignancy treat chemotherapy radiotherapy . Female subject nurse pregnant , may pregnant , contemplate pregnancy study period . Subjects deem unsuitable study investigator ( subinvestigator ) . Treatment investigational drug within 30 day precede first dose study medication . Preexisting cardiovascular disease , arrhythmia know increase risk thromboembolic event ( e.g . atrial fibrillation ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>eltrombopag</keyword>
	<keyword>thrombopoietin receptor agonist</keyword>
	<keyword>ITP</keyword>
	<keyword>blood platelet</keyword>
</DOC>